Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease.
Journal
Nature reviews. Cardiology
ISSN: 1759-5010
Titre abrégé: Nat Rev Cardiol
Pays: England
ID NLM: 101500075
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
accepted:
18
11
2019
pubmed:
19
1
2020
medline:
24
3
2020
entrez:
19
1
2020
Statut:
ppublish
Résumé
Advances in antiplatelet therapies for patients with cardiovascular disease have improved patient outcomes over time, but the challenge of balancing the risks of ischaemia and bleeding remains substantial. Moreover, many patients with cardiovascular disease have a residual risk of ischaemic events despite receiving antiplatelet therapy. Therefore, novel strategies are needed to prevent clinical events through mechanisms beyond platelet inhibition and with an acceptable associated risk of bleeding. The advent of non-vitamin K antagonist oral anticoagulants, which attenuate fibrin formation by selective inhibition of factor Xa or thrombin, has renewed the interest in dual-pathway inhibition strategies that combine an antiplatelet agent with an anticoagulant drug. In this Review, we highlight the emerging pharmacological rationale and clinical development of dual-pathway inhibition strategies for the prevention of atherothrombotic events in patients with different manifestations of cardiovascular disease, such as coronary artery disease, cerebrovascular disease and peripheral artery disease.
Identifiants
pubmed: 31953535
doi: 10.1038/s41569-019-0314-y
pii: 10.1038/s41569-019-0314-y
doi:
Substances chimiques
Anticoagulants
0
Factor Xa Inhibitors
0
Fibrinolytic Agents
0
Platelet Aggregation Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
242-257Références
Antithrombotic Trialists’ (ATT) Collaboration et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373, 1849–1860 (2009).
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348, 1329–1339 (1996).
Bhatt, D. L. et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. 354, 1706–1717 (2006).
pubmed: 16531616
Bonaca, M. P. et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N. Engl. J. Med. 372, 1791–1800 (2015).
pubmed: 25773268
Morrow, D. A. et al. Vorapaxar in the secondary prevention of atherothrombotic events. N. Engl. J. Med. 366, 1404–1413 (2012).
pubmed: 22443427
Bhatt, D. L. et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295, 180 (2006).
pubmed: 16403930
Steg, P. G. et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297, 1197–1206 (2007).
pubmed: 17374814
Bhatt, D. L. et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J. Am. Coll. Cardiol. 49, 1982–1988 (2007).
pubmed: 17498584
Libby, P. et al. Inflammation, immunity, and infection in atherothrombosis. J. Am. Coll. Cardiol. 72, 2071–2081 (2018).
pubmed: 30336831
pmcid: 6196735
Fox, K. A. A., Metra, M., Morais, J. & Atar, D. The myth of ‘stable’ coronary artery disease. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-019-0233-y (2019).
doi: 10.1038/s41569-019-0233-y
pubmed: 31358978
Angiolillo, D. J., Ueno, M. & Goto, S. Basic principles of platelet biology and clinical implications. Circ. J. 74, 597–607 (2010).
pubmed: 20197627
Ueno, M., Kodali, M., Tello-Montoliu, A. & Angiolillo, D. J. Role of platelets and antiplatelet therapy in cardiovascular disease. J. Atheroscler. Thromb. 18, 431–442 (2011).
pubmed: 21427504
Angiolillo, D. J., Capodanno, D. & Goto, S. Platelet thrombin receptor antagonism and atherothrombosis. Eur. Heart J. 31, 17–28 (2010).
pubmed: 19948715
Angiolillo, D. J. & Ferreiro, J. L. Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents. Am. J. Cardiovasc. Drugs 13, 233–250 (2013).
pubmed: 23613159
Moon, J. Y., Nagaraju, D., Franchi, F., Rollini, F. & Angiolillo, D. J. The role of oral anticoagulant therapy in patients with acute coronary syndrome. Ther. Adv. Hematol. 8, 353–366 (2017).
pubmed: 29204262
pmcid: 5703114
Cho, S. W., Franchi, F. & Angiolillo, D. J. Role of oral anticoagulant therapy for secondary prevention in patients with stable atherothrombotic disease manifestations. Ther. Adv. Hematol. 10, 2040620719861475 (2019).
pubmed: 31321012
pmcid: 6628539
Roffi, M. et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 37, 267–315 (2016).
pubmed: 26320110
Ibanez, B. et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. https://doi.org/10.1093/eurheartj/ehx393 (2017).
doi: 10.1093/eurheartj/ehx393
pubmed: 27118196
Valgimigli, M. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur. Heart J. 39, 213–260 (2018).
pubmed: 28886622
Aboyans, V. et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur. Heart J. https://doi.org/10.1093/eurheartj/ehx095 (2017).
doi: 10.1093/eurheartj/ehx095
pubmed: 28043979
Arnett, D. K. et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation https://doi.org/10.1161/CIR.0000000000000678 (2019).
doi: 10.1161/CIR.0000000000000678
pubmed: 30879355
Gerhard-Herman, M. D. et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J. Am. Coll. Cardiol. 69, e71–e126 (2017).
pubmed: 27851992
Knuuti, J. et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur. Heart J. https://doi.org/10.1093/eurheartj/ehz425 (2019).
doi: 10.1093/eurheartj/ehz425
pubmed: 30601985
Piepoli, M. F. et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J. 37, 2315–2381 (2016).
pubmed: 27222591
pmcid: 4986030
Gaziano, J. M. et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 392, 1036–1046 (2018).
pubmed: 30158069
ASCEND Study Collaborative Group et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N. Engl. J. Med. 379, 1529–1539 (2018).
McNeil, J. J. et al. Effect of aspirin on all-cause mortality in the healthy elderly. N. Engl. J. Med. 379, 1519–1528 (2018).
pubmed: 30221595
pmcid: 6433466
Zheng, S. L. & Roddick, A. J. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. JAMA 321, 277–287 (2019).
pubmed: 30667501
pmcid: 6439678
Montalescot, G. A farewell to aspirin in primary prevention? Nat. Rev. Cardiol. 16, 76–77 (2019).
pubmed: 30573760
Mahmoud, A. N., Gad, M. M., Elgendy, A. Y., Elgendy, I. Y. & Bavry, A. A. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur. Heart J. 40, 607–617 (2019).
pubmed: 30561620
Capodanno, D. Oral antithrombotic therapy after acute coronary syndromes: ‘dual antiplatelet’ or ‘dual pathway’? EuroIntervention https://doi.org/10.4244/EIJV13I7A112 (2017).
doi: 10.4244/EIJV13I7A112
pubmed: 29151434
ten Cate, H. Tissue factor-driven thrombin generation and inflammation in atherosclerosis. Thromb. Res. 129 (Suppl.), S38–S40 (2012).
pubmed: 22398011
Esmon, C. T. Targeting factor Xa and thrombin: impact on coagulation and beyond. Thromb. Haemost. 111, 625–633 (2014).
pubmed: 24336942
Borissoff, J. I., Spronk, H. M. H. & ten Cate, H. The hemostatic system as a modulator of atherosclerosis. N. Engl. J. Med. 364, 1746–1760 (2011).
pubmed: 21542745
Mostowik, M., Siniarski, A., Gołębiowska-Wiatrak, R., Nessler, J. & Gajos, G. Prolonged CRP increase after percutaneous coronary intervention is associated with high thrombin concentrations and low platelet’ response to clopidogrel in patients with stable angina. Adv. Clin. Exp. Med. 24, 979–985 (2015).
pubmed: 26771969
Brummel-Ziedins, K. et al. Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition. J. Thromb. Haemost. 6, 104–110 (2008).
pubmed: 17944993
Becker, E. M. et al. Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis. J. Thromb. Haemost. 10, 2470–2480 (2012).
pubmed: 23083002
Perzborn, E., Heitmeier, S. & Laux, V. Effects of rivaroxaban on platelet activation and platelet-coagulation pathway interaction: in vitro and in vivo studies. J. Cardiovasc. Pharmacol. Ther. 20, 554–562 (2015).
pubmed: 25848131
pmcid: 4598653
Álvarez, E., Paradela-Dobarro, B., Raposeiras-Roubín, S. & González-Juanatey, J. R. Protective, repairing and fibrinolytic effects of rivaroxaban on vascular endothelium. Br. J. Clin. Pharmacol. 84, 280–291 (2018).
pubmed: 28940408
Andreotti, F., Testa, L., Biondi-Zoccai, G. G. L. & Crea, F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur. Heart J. 27, 519–526 (2006).
pubmed: 16143706
Kirchhof, P. et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J. 37, 2893–2962 (2016).
pubmed: 27567408
Sardar, P. et al. New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons. PLOS ONE 8, e77694 (2013).
pubmed: 24204920
pmcid: 3808395
Wallentin, L. et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 362, 789–797 (2003).
pubmed: 13678873
Oldgren, J. et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur. Hear. J. 32, 2781–2789 (2011).
Steg, P. G. et al. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur. Heart J. 32, 2541–2554 (2011).
pubmed: 21878434
pmcid: 3295208
Goldstein, S. et al. Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome. Thromb. Haemost. https://doi.org/10.1160/TH13-07-0543 (2014).
doi: 10.1160/TH13-07-0543
pubmed: 24671450
APPRAISE Steering Committee and Investigators et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the apixaban for prevention of acute ischemic and safety events (APPRAISE) trial. Circulation 119, 2877–2885 (2009).
Alexander, J. H. et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N. Engl. J. Med. 365, 699–708 (2011).
pubmed: 21780946
Mega, J. L. et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 374, 29–38 (2009).
pubmed: 19539361
Mega, J. L. et al. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med. 366, 9–19 (2012).
pubmed: 22077192
Gibson, W. J. et al. Safety and efficacy of rivaroxaban when added to aspirin monotherapy among stabilized post‐acute coronary syndrome patients: a pooled analysis study of ATLAS ACS‐TIMI 46 and ATLAS ACS 2‐TIMI 51. J. Am. Heart Assoc. 8, e009451 (2019).
pmcid: 6474929
Ohman, E. M. et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet 389, 1799–1808 (2017).
pubmed: 28325638
Capodanno, D. et al. Management of antithrombotic therapy in atrial fibrillation patients undergoing PCI: JACC state-of-the-art review. J. Am. Coll. Cardiol. 74, 83–99 (2019).
pubmed: 31272556
Dewilde, W. J. et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381, 1107–1115 (2013).
pubmed: 23415013
Capodanno, D. et al. Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nat. Rev. Cardiol. 15, 480–496 (2018).
pubmed: 29973709
Gibson, C. M. et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N. Engl. J. Med. 375, 2423–2434 (2016).
pubmed: 27959713
Gibson, C. M. et al. Recurrent hospitalization among patients with atrial fibrillation undergoing intracoronary stenting treated with 2 treatment strategies of rivaroxaban or a dose-adjusted oral vitamin k antagonist treatment strategy: clinical perspective. Circulation 135, 323–333 (2017).
pubmed: 27881555
pmcid: 5266420
Cannon, C. P. et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N. Engl. J. Med. 377, 1513–1524 (2017).
pubmed: 28844193
Lopes, R. D. et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1817083 (2019).
doi: 10.1056/NEJMoa1817083
pubmed: 31553841
Vranckx, P. et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet https://doi.org/10.1016/S0140-6736(19)31872-0 (2019).
doi: 10.1016/S0140-6736(19)31872-0
pubmed: 31492505
Capodanno, D. & Angiolillo, D. J. Dual antithrombotic therapy for atrial fibrillation and PCI. Lancet https://doi.org/10.1016/S0140-6736(19)31954-3 (2019).
doi: 10.1016/S0140-6736(19)31954-3
pubmed: 31492502
Franchi, F. et al. Effects of edoxaban on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel: results of the EDOX-APT study. Thromb. Haemost. https://doi.org/10.1055/s-0039-1695772 (2019).
doi: 10.1055/s-0039-1695772
pubmed: 31470444
Golwala, H. B. et al. Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. Eur. Heart J. 39, 1726–1735a (2018).
pubmed: 29668889
pmcid: 5951099
Lopes, R. D. et al. Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials. JAMA Cardiol. https://doi.org/10.1001/jamacardio.2019.1880 (2019).
doi: 10.1001/jamacardio.2019.1880
pubmed: 31799984
pmcid: 6439551
Gargiulo, G. et al. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur. Heart H. 7, 3757–3767 (2019).
Eikelboom, J. W. et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N. Engl. J. Med. 377, 1319–1330 (2017).
pubmed: 28844192
Sharma, M. et al. Stroke outcomes in the COMPASS trial. Circulation 139, 1134–1145 (2019).
pubmed: 30667279
Moayyedi, P. et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology 157, 682–691.e2 (2019).
pubmed: 31152740
Moayyedi, P. et al. Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double-blind, placebo-controlled trial. Gastroenterology 157, 403–412.e5 (2019).
pubmed: 31054846
Anand, S. S. et al. Rivaroxaban plus aspirin versus aspirin in relation to vascular risk in the COMPASS trial. J. Am. Coll. Cardiol. 73, 3271–3280 (2019).
pubmed: 31248548
Branch, K. R. et al. Rivaroxaban with or without aspirin in patients with heart failure and chronic coronary or peripheral artery disease: the COMPASS trial. Circulation https://doi.org/10.1161/CIRCULATIONAHA.119.039609 (2019).
doi: 10.1161/CIRCULATIONAHA.119.039609
pubmed: 31195817
pmcid: 6693980
Fox, K. A. A. et al. Rivaroxaban plus aspirin in patients with vascular disease and renal dysfunction: from the compass trial. J. Am. Coll. Cardiol. 73, 2243–2250 (2019).
pubmed: 31072566
Connolly, S. J. et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 391, 205–218 (2018).
pubmed: 29132879
Lamy, A. et al. Rivaroxaban, aspirin, or both to prevent early coronary bypass graft occlusion: the COMPASS-CABG study. J. Am. Coll. Cardiol. 73, 121–130 (2019).
pubmed: 30654882
Anand, S. S. et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 391, 219–229 (2018).
pubmed: 29132880
Anand, S. S. et al. Major adverse limb events in lower extremity peripheral artery disease: COMPASS trial. J. Am. Coll. Cardiol. 71, 2306–2315 (2018).
pubmed: 29540326
Borissoff, J. I., Spronk, H. M. H., Heeneman, S. & ten Cate, H. Is thrombin a key player in the ‘coagulation-atherogenesis’ maze? Cardiovasc. Res. 82, 392–403 (2009).
pubmed: 19228706
Zannad, F. et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N. Engl. J. Med. 379, 1332–1342 (2018).
pubmed: 30146935
Greenberg, B. et al. Association of rivaroxaban with thromboembolic events in patients with heart failure, coronary disease, and sinus rhythm: a post hoc analysis of the COMMANDER HF trial. JAMA Cardiol. https://doi.org/10.1001/jamacardio.2019.1049 (2019).
doi: 10.1001/jamacardio.2019.1049
pubmed: 31017637
Capodanno, D. & Angiolillo, D. J. Antithrombotic therapy for prevention of cerebral thromboembolic events after transcatheter aortic valve replacement. JACC Cardiovasc. Interv. 10, 1366–1369 (2017).
pubmed: 28527775
Windecker, S. et al. Trial design: rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: rationale and design of the GALILEO study. Am. Heart J. 184, 81–87 (2017).
pubmed: 27892890
Dangas, G. D. et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1911425 (2019).
doi: 10.1056/NEJMoa1911425
pubmed: 31733182
Collet, J.-P. et al. Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: the randomized ATLANTIS trial. Am. Heart J. 200, 44–50 (2018).
pubmed: 29898848
Van Mieghem, N. M. et al. Edoxaban versus standard of care and their effects on clinical outcomes in patients having undergone transcatheter aortic valve implantation in atrial fibrillation — rationale and design of the ENVISAGE-TAVI AF trial. Am. Heart J. 205, 63–69 (2018).
pubmed: 30172099
Capodanno, D., Alfonso, F., Levine, G. N., Valgimigli, M. & Angiolillo, D. J. Dual antiplatelet therapy: appraisal of the ACC/AHA and ESC focused updates. J. Am. Coll. Cardiol. 72, 103–119 (2018).
Zeymer, U., Schrage, B. & Westermann, D. Dual pathway inhibition with low-dose direct factor Xa inhibition after acute coronary syndromes — why is it not used in clinical practice? Thromb. Haemost. 118, 1528–1534 (2018).
pubmed: 30103248
Angiolillo, D. J. et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention. Circulation 138, 527–536 (2018).
pubmed: 30571525
Matsumura-Nakano, Y. et al. Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation. Circulation 139, 604–616 (2019).
pubmed: 30586700
Yasuda, S. et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1904143 (2019).
doi: 10.1056/NEJMoa1904143
pubmed: 31851811
van Rein, N. et al. Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy. Circulation 139, 775–786 (2019).
pubmed: 30586754
Angiolillo, D. J. et al. Variability in individual responsiveness to clopidogrel. J. Am. Coll. Cardiol. 49, 1505–1516 (2007).
pubmed: 17418288
Fox, K. A. A. et al. Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add? Eur. Heart J. https://doi.org/10.1093/eurheartj/ehy347 (2018).
doi: 10.1093/eurheartj/ehy347
pubmed: 30202849
pmcid: 6220125
Darmon, A. et al. External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. Eur. Heart J. 39, 750–757a (2018).
pubmed: 29186454
Hussain, M. A. et al. Antithrombotic therapy for peripheral artery disease: recent advances. J. Am. Coll. Cardiol. 71, 2450–2467 (2018).
pubmed: 29793635
Boden, W. E. & Bhatt, D. L. Will COMPASS point to a new direction in thrombotic risk reduction in patients with stable cardiovascular disease? Circulation 138, 858–860 (2018).
pubmed: 30354448
Sumaya, W., Geisler, T., Kristensen, S. D. & Storey, R. F. Dual antiplatelet or dual antithrombotic therapy for secondary prevention in high-risk patients with stable coronary artery disease? Thromb. Haemost. 19, 1583–1589 (2019).
pubmed: 30836389
Hiatt, W. R. et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N. Engl. J. Med. 376, 32–40 (2017).
pubmed: 27959717
Cacoub, P. P. et al. Patients with peripheral arterial disease in the CHARISMA trial. Eur. Heart J. 30, 192–201 (2009).
pubmed: 19136484
Bonaca, M. P. et al. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J. Am. Coll. Cardiol. 67, 2719–2728 (2016).
pubmed: 27046162
Bonaca, M. P. et al. Vorapaxar in patients with peripheral artery disease: results from TRA2°P-TIMI 50. Circulation 127, 1522–1529 (2013).
pubmed: 23501976
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02504216 (2019).